Linde PLC vs Zimmer Biomet Holdings Inc — how do they compare? Linde PLC trades at $489.54 (market cap $227.01B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.65B). The key difference: Linde PLC is far larger — about 12.2× Zimmer Biomet Holdings Inc's market cap, and Linde PLC pays the higher dividend (1.3%). Which is the better fit depends on your goals.
| LIN | ZBH | |
|---|---|---|
Market Cap | $227.01B | $18.65B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $107.71 |
52-Week Low | $389.38 | $79.58 |
Enterprise Value | $250.13B | $25.72B |
Dividend Yield | 1.3% | 0.98% |
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $490.53, up 0.11% on the day, with a bearish technical signal despite strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.50 surpassing expectations. Revenue grew to $34.0B in 2025, with a net income margin of 20.43%. Analysts maintain a strong buy consensus with a $553.60 price target, highlighting robust profitability and dividend growth.
Outlook remains positive due to earnings momentum and sustainability leadership, but risks include elevated valuation multiples and rising debt-to-asset ratio. The stock offers steady income with a $1.60 dividend, yet technical weakness near support at $489 warrants caution for near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →